证券代码：688293 证券简称：奥浦迈 公告编号：2025-096 上海奥浦迈生物科技股份有限公司 第二届监事会第十五次会议决议公告 其他规范性文件要求对《上海奥浦迈生物科技股份有限公司发行股份及支付现金 购买资产并募集配套资金报告书（草案）》及其摘要涉及的部分内容进行修订更 新。 表决结果：3票同意、0票反对、0票弃权；获全体监事一致通过。 具体内容详见公司于同日刊载于上海证券交易所网站（www.sse.com.cn）的 《上海奥浦迈生物科技股份有限公司发行股份及支付现金购买资产并募集配套 资金报告书（申报稿）》（二次修订稿）《上海奥浦迈生物科技股份有限公司发 行股份及支付现金购买资产并募集配套资金报告书（草案）摘要》（二次修订稿）。 2、审议通过了《关于本次交易相关的上市公司经审阅的备考财务报告的议 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届监事会第十五次会议于2025年11月10日通过现场表决与通讯相结合的方式召 开 ...

议案内容：本次交易中评估机构对上市公司拟合并对价分摊涉及的标的公司澎 立生物可辨认净资产公允价值资产评估工作已完成，同时结合与上交所进一步审核 意见，公司根据《证券法》以及《上市公司重大资产重组管理办法》等相关法律法 规及其他规范性文件要求对《上海奥浦迈生物科技股份有限公司发行股份及支付现 金购买资产并募集配套资金报告书（草案）》及其摘要涉及的部分内容进行修订更新。 表决结果：2 票同意、1 票反对、0 票弃权；获独立董事专门会议审议通过。 上海奥浦迈生物科技股份有限公司 第二届董事会独立董事专门会议第七次会议决议 上海奥浦迈生物科技股份有限公司（以下简称"公司"）第二届董事会独立董事 专门会议第七次会议于 2025 年 11 月 10 日通过现场表决与通讯相结合的方式召开。 本次会议应到独立董事 3 人，实到独立董事 3 人。本次会议的召集、召开程序符合 相关法律、行政法规、部门规章、规范性文件以及《上海奥浦迈生物科技股份有限 公司独立董事工作制度》的规定。 经与会独立董事审议表决，形成的会议决议如下： 一、审议通过了《关于修订<上海奥浦迈生物科技股份有限公司发行股份及支付 现金购买资产并募集配套资金报告书 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届董事会第十六次会议于2025年11月10日通过现场表决与通讯相结合的方式召 开。本次会议通知及相关资料已于2025年11月3日送达全体董事。本次会议由董 事长肖志华先生召集并主持，会议应出席董事7名，实际出席董事7名，本次会议 的召集、召开方式符合相关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定，会议决议合法有效。 证券代码：688293 证券简称：奥浦迈 公告编号：2025-095 上海奥浦迈生物科技股份有限公司 第二届董事会第十六次会议决议公告 1、审议通过了《关于修订<上海奥浦迈生物科技股份有限公司发行股份及 支付现金购买资产并募集配套资金报告书（草案）>及其摘要的议案》 本次交易中评估机构对上市公司拟合并对价分摊涉及的标的公司澎立生物 可辨认净资产公允价值资产评估工作已完成，同时结合上交所进一步审核意见， 公司根据《证券法》以及《上市公司重大资产重组管理办法》等 ...

Group 1 - The core point of the article is that Aopumai (SH 688293) held its 16th meeting of the second board on November 10, 2025, to review financial reports related to a specific transaction [1] - Aopumai's revenue composition for the year 2024 is as follows: 82.16% from culture media business, 17.68% from CDMO services, and 0.16% from leasing income [1] - As of the report, Aopumai has a market capitalization of 7 billion yuan [1]

11月10日，奥浦迈涨5%，截至发稿，报58.80元/股，成交3087.82万元，换手率0.47%，总市值66.93亿 元。 资料显示，上海奥浦迈生物科技股份有限公司位于上海市浦东新区紫萍路908弄28号楼，成立日期2013 年11月27日，上市日期2022年9月2日，公司主营业务涉及从事细胞培养产品与服务。主营业务收入构成 为：产品87.34%，服务12.53%，其他0.13%。 从奥浦迈十大流通股东角度 数据显示，工银瑞信基金旗下1只基金位居奥浦迈十大流通股东。工银前沿医疗股票A（001717）三季 度增持40万股，持有股数330.01万股，占流通股的比例为2.91%。根据测算，今日浮盈赚取约924.02万 元。 工银前沿医疗股票A（001717）成立日期2016年2月3日，最新规模96.36亿。今年以来收益21.28%，同 类排名2685/4216；近一年收益12.68%，同类排名2778/3917；成立以来收益219.1%。 工银前沿医疗股票A（001717）基金经理为赵蓓。 截至发稿，赵蓓累计任职时间10年361天，现任基金资产总规模172.23亿元，任职期间最佳基金回报 219.1%， 任职期间最 ...

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1]. Core Views - The report highlights a positive change in the specialty raw materials sector, recommending companies such as Aorite and Prolo Pharmaceuticals [1]. - The report suggests that the Q3 performance of raw material pharmaceutical companies has reached a bottom, indicating potential recovery in profitability as high-cost inventory is consumed [19][20]. Summary by Sections Investment Highlights - The recommended sub-industry rankings are: Innovative Drugs > Research Services > CXO > Traditional Chinese Medicine > Medical Devices > Pharmacies [3][12]. - Specific stock recommendations include: - From raw materials: Aorite, Qianhong Pharmaceutical - From Traditional Chinese Medicine: Zorui Pharmaceutical, Fangsheng Pharmaceutical, Dong'e Ejiao - From medical devices: United Imaging Healthcare, Yuyue Medical - From AI pharmaceuticals: Jingtai Holdings - From GLP-1 sector: Lianbang Pharmaceutical, Borui Pharmaceutical, Zhongsheng Pharmaceutical, and Innovent Biologics - From PD-1/VEGF dual antibodies: Sanofi Biopharmaceuticals, Kangfang Biologics, and Rongchang Biopharmaceuticals - From innovative drugs: Innovent Biologics, BeiGene, HengRui Medicine, Zai Lab, Baillie Tianheng, Kelun Pharmaceutical, Dize Pharmaceutical, and Haizheng Pharmaceutical [3][15]. Industry Trends - The A-share pharmaceutical index has seen a year-to-date increase of 18.2%, while the Hang Seng Biotechnology Index has increased by 76.6% [6][11]. - The report notes that the raw material pharmaceutical sector is under pressure due to high base effects and declining prices, with significant revenue impacts [19][20]. R&D Progress and Company Dynamics - Recent approvals include Novartis' radioligand therapy drug, which received dual indications for prostate cancer treatment [2]. - The report provides an overview of ongoing clinical trials and drug approvals, emphasizing the importance of innovation in the pharmaceutical sector [30]. Market Performance - The report indicates that the pharmaceutical sector has experienced adjustments, with notable stock performances including significant gains for companies like Hezhong China (+61%) and Wanze Shares (+30%) [11]. - The report also highlights the performance of various pharmaceutical stocks, noting both gains and losses in the market [16][17]. Raw Material Pricing Trends - The price of 6-APA has dropped significantly, from 370 RMB/kg in 2022 to 180 RMB/kg in October 2025, a decrease of 51% [23]. - The price of Amoxicillin has also decreased from 320 RMB/kg in January 2023 to 190 RMB/kg in October 2025, a decline of 41% [23]. Conclusion - The report suggests that as high-cost inventory is depleted, the gross margins for raw material producers are expected to improve, indicating a potential recovery in profitability for companies like Fuxiang Pharmaceutical and Lukang Pharmaceutical [19][23].

Group 1 - The core point of the news is that Aopumai's stock price has decreased by 5.02%, currently trading at 55.87 CNY per share, with a total market capitalization of 6.359 billion CNY [1] - Aopumai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company specializes in cell culture products and services, with product revenue accounting for 87.34% and service revenue for 12.53% [1] Group 2 - From the perspective of major fund holdings, Guotai Fund has a significant position in Aopumai, with its Guotai National Policy Driven Flexible Allocation Mixed A Fund holding 3,140 shares, representing 0.65% of the fund's net value [2] - The Guotai National Policy Driven Flexible Allocation Mixed A Fund has a total scale of 21.707 million CNY and has achieved a year-to-date return of 3.97% [2] - The fund manager, Deng Shifeng, has a tenure of 17 years and has achieved the best fund return of 167.36% during his management period [2]

Core Insights - The article highlights the establishment of various investment funds across different regions in China, focusing on strategic industries and innovation-driven sectors. Group 1: Fund Establishments - A central enterprise strategic emerging industry development fund was launched in Beijing with an initial scale of 510 billion RMB, involving major state-owned enterprises as contributors [2] - The Zhejiang Social Security Science and Technology Innovation Fund was established with an initial scale of 500 billion RMB, aimed at supporting key areas of technological innovation [3] - The first biomanufacturing industry fund in Shanghai was initiated, combining resources from industry leaders and venture capital to drive technological breakthroughs [4] Group 2: Regional Funds - Chengdu established a high-level talent innovation and entrepreneurship fund, focusing on early-stage investments to support talent and technology transfer [5][6] - Dongguan's Songshan Lake completed the registration of a 100 billion RMB mother fund to promote technological finance and regional industrial upgrades [7] - Wuhan launched its first concept verification fund group with an annual funding pool of 112.5 million RMB to support startup projects [8] Group 3: Sector-Specific Funds - The Hebei Xiong'an concept verification fund was set up with a focus on aerospace information and biotechnology, with an initial scale of 20 million RMB [9] - The Jilin Province Ice and Snow Economy Fund was established with a total scale of 500 million RMB, targeting the ice and snow tourism and technology sectors [11] - The Zhuhai Zuguang New Intelligence Fund was launched to support high-end intelligent manufacturing, marking a significant step in the region's industrial investment [12] Group 4: Investment Strategies - The Chengdu fund emphasizes market-oriented operations to facilitate talent and technology commercialization [6] - The Dongguan fund aims to create a comprehensive fund system covering the entire lifecycle of enterprises through collaboration with various investment institutions [7] - The Jiangsu Yangzhou Aerospace Industry Fund focuses on strategic emerging industries, leveraging a significant capital structure to enhance investment capabilities [14]

Investment Rating - The report maintains a "Recommended" rating for the company [1][7][11] Core Views - The company reported Q3 2025 revenue of 0.94 billion yuan, a year-on-year increase of 29.80%, and a net profit of 0.12 billion yuan, up 283.59% year-on-year [4] - The CDMO service business experienced a slight decline in revenue, impacted by external conditions and fluctuating customer demand, while the cell culture product business saw significant growth [7] - The number of participating pipelines continues to grow, with 311 pipelines as of Q3, including 34 in Phase 3 clinical trials and 13 commercial projects [7] - The profit forecast for 2025-2027 has been adjusted to net profits of 0.81 billion, 1.18 billion, and 1.66 billion yuan, respectively, reflecting a high certainty of performance growth [7] Financial Summary - For 2025, the company expects revenue of 2.72 billion yuan, a 25.79% increase year-on-year, and a net profit of 0.49 billion yuan, up 81.48% year-on-year [4] - The projected revenue for the upcoming years is as follows: 2024A: 2.97 billion yuan, 2025E: 3.74 billion yuan, 2026E: 4.77 billion yuan, and 2027E: 6.06 billion yuan [6] - The net profit projections for the same years are: 2024A: 0.21 billion yuan, 2025E: 0.81 billion yuan, 2026E: 1.18 billion yuan, and 2027E: 1.66 billion yuan [6][9] - The gross margin is expected to improve from 53.0% in 2024A to 59.3% in 2027E, while the net margin is projected to increase from 7.1% to 27.3% over the same period [9] Key Financial Ratios - The company’s return on equity (ROE) is projected to rise from 1.0% in 2024A to 6.7% in 2027E [9] - The asset-liability ratio is expected to remain low, around 7.6% in 2025E [9] - The price-to-earnings (P/E) ratio is projected to decrease from 312.0 in 2024A to 39.6 in 2027E, indicating improving valuation [9]

Group 1 - The core point of the news is the performance and financial metrics of Aopumai Biotechnology Co., Ltd., which saw a stock price increase of 5.03% to 60.60 CNY per share, with a total market capitalization of 6.898 billion CNY [1] - Aopumai was established on November 27, 2013, and went public on September 2, 2022, focusing on cell culture products and services [1] - The company's revenue composition is primarily from products (87.34%), followed by services (12.53%) and other sources (0.13%) [1] Group 2 - According to data, Aopumai is a significant holding in the Guangfa Balanced Growth Mixed A Fund, which held 1.5283 million shares, accounting for 2.87% of the fund's net value, ranking as the ninth largest holding [2] - The Guangfa Balanced Growth Mixed A Fund has achieved a year-to-date return of 50.18%, ranking 1148 out of 8154 in its category, and a one-year return of 48.28%, ranking 1193 out of 8046 [2] - The fund manager, Yang Dong, has been in position for 4 years and 123 days, with a total asset scale of 23.666 billion CNY and a best fund return of 103.21% during his tenure [2]